A novel heterozygous frameshift c.277del p.Thr93Leufs*21 mutation in SERPINC1 associated with type 1 antithrombin deficiency
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30986 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Riten Kumar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Antithrombin III, Frameshift Mutation, Antithrombin III Deficiency, Heterozygote. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
- Genomic Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Riten Kumar
Zitieren
APA
Kumar, R., Duzan, J., Drake, E., & Dawson, J. (2024). A novel heterozygous frameshift c.277del p.Thr93Leufs*21 mutation in SERPINC1 associated with type 1 antithrombin deficiency. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30986
Vancouver
Kumar R, Duzan J, Drake E, Dawson J. A novel heterozygous frameshift c.277del p.Thr93Leufs*21 mutation in SERPINC1 associated with type 1 antithrombin deficiency. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30986
BibTeX
@article{Kumar2024,
author = {Kumar, Riten and Duzan, Juliann and Drake, Emily and Dawson, Jennifer},
title = {A novel heterozygous frameshift c.277del p.Thr93Leufs*21 mutation in SERPINC1 associated with type 1 antithrombin deficiency},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30986}
}
EUVIMED